Moreover, the antibody response to the ZRF1 antigen was found to be higher in sera of patients with breast invasive ductal carcinoma particularly with less aggressive tumor phenotype [45]. This evidence concerns the gene DNAJC2 and invasive ductal breast carcinoma.